采纳股份：2025年全年净利润同比预减88.70%—92.47%

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a decrease of 88.70% to 92.47% compared to the previous year, with net profit attributed to shareholders estimated between 4 million to 6 million yuan [1] Group 1: Financial Performance - The projected net profit for 2025 is between 4 million to 6 million yuan, indicating a substantial year-on-year decrease [1] - The net profit excluding non-recurring losses is expected to be between -12 million to -7 million yuan [1] Group 2: Factors Affecting Performance - The decline in performance is primarily due to the impact of the U.S. FDA import warnings and increased tariffs, which have altered the company's product sales structure and reduced overall gross profit margins [1] - The company is accelerating the construction and production of its facility in Cambodia to adapt to external environmental changes, which has led to increased fixed costs and initial production inefficiencies [1] - Additional costs have been incurred for the registration and certification of new products as part of the company's business layout strategy [1] - The company has recognized impairment losses on certain assets based on prudence principles in accordance with accounting standards [1]